Consultation on a proposed interim approach to speed up the review of certain pediatric drugs
Current status: Open
Opened on September 14, 2026, and will close to new input on October 23, 2026
We're proposing a new interim approach to speed up the review of certain pediatric drugs. Under this new approach, we plan to review certain pediatric drug submissions within 180 days.
Join in: how to participate
We're consulting with manufacturers and other interested parties on a proposed interim approach for certain pediatric drug submissions. We will use the feedback we receive to refine this proposed interim approach.
Send us an email
Send an email to policy_bureau_enquiries@hc-sc.gc.ca with your ideas or comments. In the subject line of the email, use "Comments on a proposed interim approach to speed up the review of certain pediatric drugs".
Who is the focus of this consultation
We will engage with:
- industry
- health care professionals
Key questions for discussion
Through this consultation, Health Canada is seeking feedback on:
- proposed eligibility criteria and review timelines
- any other general suggestions or questions for us to consider
Related information
- Proposed interim approach to speed up the review of certain pediatric drugs: Notice
- Guidance for industry - Priority review of drug submissions
- Guidance Document: Notice of compliance with conditions (NOC/c)
- Guidance on management of drug submissions and applications
Contact us
Bureau of Policy, Science and International Programs
Pharmaceutical Drugs Directorate
Health Products and Food Branch
Health Canada
Email: policy_bureau_enquiries@hc-sc.gc.ca
From: Health Canada